Literature DB >> 26201922

Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis.

Yusuke Kawamura1,2, Satoshi Saitoh3,4, Yasuji Arase3,4, Kenji Ikeda3,4, Taito Fukushima3,4, Tasuku Hara3,4, Yuya Seko3,4, Tetsuya Hosaka3,4, Masahiro Kobayashi3,4, Hitomi Sezaki3,4, Norio Akuta3,4, Fumitaka Suzuki3,4, Yoshiyuki Suzuki3,4, Kei Fukuzawa4,5, Yusuke Hamada4,5, Junji Takahashi4,5, Mariko Kobayashi4,6, Hiromitsu Kumada3,4.   

Abstract

BACKGROUND: The definitive diagnosis of nonalcoholic steatohepatitis (NASH) is currently based on histopathological assessment. This study aimed to elucidate the utility of a novel noninvasive method, three-dimensional magnetic resonance imaging (3D-MRI), for diagnosing advanced fibrosis in patients with NASH, using histopathological diagnosis as the reference standard.
METHODS: This retrospective study included 30 consecutive patients who had been diagnosed with NASH by histopathology and had undergone 3D-MRI before biopsy. 3D-MRI provided a three-dimensional reconstruction of the liver from contrast-enhanced hepatobiliary phase MR images. In the present study, histopathological advanced fibrosis was defined as stage 3 and 4 NASH. Advanced fibrosis, diagnosed by 3D-MRI, was considered to be diffuse irregularity of the entire surface of the liver. The diagnostic features of 3D-MRI and the noninvasive evaluation systems (APRI, FIB-4 index, and BARD score) for identifying advanced and nonadvanced fibrosis of NASH were determined and compared.
RESULTS: Nine (30 %) of the 30 study patients were diagnosed histopathologically with advanced fibrosis, and 11 (37 %) of 30 patients were diagnosed with advanced fibrosis using 3D-MRI. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 3D-MRI for diagnosing advanced fibrosis were 100, 90, 82, and 100 %, respectively. The sensitivities of APRI, the FIB-4 index, and BARD score ranged from 78 to 89 %, the specificities from 71 to 90 %, the PPVs from 54 to 78 %, and the NPVs from 88 to 94 %.
CONCLUSION: Compared with the common noninvasive methods for diagnosing advanced fibrosis associated with NASH, 3D-MRI was more accurate.

Entities:  

Keywords:  3D-MRI; Advanced fibrosis; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Virtual MR-laparoscopy

Year:  2013        PMID: 26201922     DOI: 10.1007/s12072-012-9419-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  30 in total

1.  Safety and feasibility of a new minimally invasive diagnostic laparoscopy technique.

Authors:  I Helmreich-Becker; K H Meyer zum Büschenfelde; A W Lohse
Journal:  Endoscopy       Date:  1998-11       Impact factor: 10.093

2.  Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography.

Authors:  Masato Yoneda; Kaori Suzuki; Shingo Kato; Koji Fujita; Yuichi Nozaki; Kunihiro Hosono; Satoru Saito; Atsushi Nakajima
Journal:  Radiology       Date:  2010-06-07       Impact factor: 11.105

Review 3.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.

Authors:  Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

Review 6.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

Review 7.  Epidemiology of non-alcoholic fatty liver disease in China.

Authors:  Jian-Gao Fan; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2008-11-06       Impact factor: 25.083

8.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

Authors:  S A Harrison; D Oliver; H L Arnold; S Gogia; B A Neuschwander-Tetri
Journal:  Gut       Date:  2008-04-04       Impact factor: 23.059

9.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings.

Authors:  Alexander Huppertz; Thomas Balzer; Anthony Blakeborough; Josy Breuer; Andrea Giovagnoni; Gertraud Heinz-Peer; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Mueller; Peter Reimer; Philip J Robinson; Michael Strotzer; Matthias Taupitz; Thomas J Vogl
Journal:  Radiology       Date:  2004-01       Impact factor: 11.105

10.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

Authors:  M Yoneda; M Yoneda; H Mawatari; K Fujita; H Endo; H Iida; Y Nozaki; K Yonemitsu; T Higurashi; H Takahashi; N Kobayashi; H Kirikoshi; Y Abe; M Inamori; K Kubota; S Saito; M Tamano; H Hiraishi; S Maeyama; N Yamaguchi; S Togo; A Nakajima
Journal:  Dig Liver Dis       Date:  2007-12-20       Impact factor: 4.088

View more
  2 in total

1.  Detecting fibrosis without a liver biopsy: getting to the fat of the issue.

Authors:  Yan Bi; Sudhakar K Venkatesh; Vijay H Shah
Journal:  Hepatol Int       Date:  2013-07-18       Impact factor: 6.047

2.  Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Tatsuya Hayashi; Satoshi Saitoh; Kei Fukuzawa; Yoshinori Tsuji; Junji Takahashi; Yusuke Kawamura; Norio Akuta; Masahiro Kobayashi; Kenji Ikeda; Takeshi Fujii; Tosiaki Miyati; Hiromitsu Kumada
Journal:  Gut Liver       Date:  2017-09-15       Impact factor: 4.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.